Edwards Lifesciences traded at $85.22 this Wednesday March 4th, decreasing $0.06 or 0.07 percent since the previous trading session. Looking back, over the last four weeks, Edwards Lifesciences lost 9.12 percent. Over the last 12 months, its price rose by 16.98 percent. Looking ahead, we forecast Edwards Lifesciences to be priced at 83.82 by the end of this quarter and at 76.36 in one year, according to Trading Economics global macro models projections and analysts expectations.
Edwards Lifesciences Corporation is a manufacturer of heart valve systems and repair products used to replace or repair a patient's diseased or defective heart valve. The Company is engaged in patient-focused innovations for structural heart disease and critical care monitoring. Its segments include United States, Europe, Japan and Rest of World. Its products and technologies are categorized into four main areas: Transcatheter Aortic Valve Replacement, Transcatheter Mitral and Tricuspid Therapies, Surgical Structural Heart and Critical Care. It also develops hemodynamic monitoring systems that are used to measure a patient's cardiovascular function in the hospital setting. The Edwards SAPIEN family of valves, including Edwards SAPIEN XT, the Edwards SAPIEN 3, and the Edwards SAPIEN 3 Ultra transcatheter aortic heart valves are used to treat heart valve disease. Its Critical Care products are manufactured in its facilities located in Puerto Rico and the Dominican Republic.